Celldex Therapeutics Inc expected to post a loss of 75 cents a share - Earnings Preview

Celldex Therapeutics

06/05/2025 12:29

Celldex Therapeutics Inc CLDX.OQ CLDX.O is expected to show a rise in quarterly revenue when it reports  results on May 8 (estimated) for the period ending March 31 2025

The Hampton New Jersey-based  company is expected to report a 570.8% increase in revenue to $1.047 million from $156 thousand a year ago, according to the mean estimate from 10 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Celldex Therapeutics Inc is for a loss of 75 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 0.1% in the last three months. ​

Wall Street's median 12-month price target for Celldex Therapeutics Inc is $63.50​, above​ its last closing price of $20.29. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.72
-0.73
-0.71
Beat
3.3
Sep. 30 2024
-0.66
-0.67
-0.64
Beat
4.8
Jun. 30 2024
-0.59
-0.59
-0.54
Beat
8.1​
Mar. 31 2024
-0.70
-0.69
-0.56
Beat
19.3
​​Dec. 31 2023
-0.76
-0.74
-0.83
Missed
-11.6
Sep. 30 2023
-0.68
-0.68
-0.81
Missed
-19.4​
Jun. 30 2023
-0.67
-0.67
-0.65
Beat
2.5
Mar. 31 2023
-0.63
-0.63
-0.62
Beat
1.9

This summary was machine generated May 6 at 11:29 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)